

NOVEN PHARMACEUTICALS INC  
Form SC 13G/A  
October 10, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1) \*

Noven Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock, \$0.0001 par value

-----  
(Title of Class of Securities)

670009109

-----  
(CUSIP Number)

September 28, 2007

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G/A

Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (03-06)

Page 1 of 4 pages

-----  
CUSIP No. 670009109  
-----

13G

-----  
1. Name of Reporting Person  
I.R.S. Identification No. of above Person  
  
Goldman Sachs Asset Management, L.P.

-----  
2. Check the Appropriate Box if a Member of a Group  
  
(a)   
(b)

-----  
3. SEC Use Only

-----  
4. Citizenship or Place of Organization  
  
Delaware

-----  
5. Sole Voting Power  
  
Number of 1,357,766  
Shares

-----  
6. Shared Voting Power  
  
Beneficially 0  
Owned by

-----  
7. Sole Dispositive Power  
  
Each 1,357,866  
Reporting Person

-----  
8. Shared Dispositive Power  
  
With: 0

-----  
9. Aggregate Amount Beneficially Owned by Each Reporting Person  
  
1,357,866

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G/A

-----  
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares

[\_]

-----  
11. Percent of Class Represented by Amount in Row (9)

5.5%

-----  
12. Type of Reporting Person

IA  
-----

Page 2 of 4 pages

Item 4. Ownership. \*

- (a). Amount beneficially owned:  
See the response(s) to Item 9 on the attached cover page(s).
- (b). Percent of Class:  
See the response(s) to Item 11 on the attached cover page(s).
- (c). Number of shares as to which such person has:
  - (i). Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
  - (ii). Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
  - (iii). Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
  - (iv). Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

-----  
\* In accordance with Securities and Exchange Commission ("SEC") Release No.

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G/A

34-39538 (January 12, 1998), this filing reflects the securities beneficially owned by Goldman Sachs Asset Management, L.P. ("GSAM LP"). GSAM LP, an investment advisor, disclaims beneficial ownership of any securities managed, on GSAM LP's behalf, by third parties.

Page 3 of 4 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 10, 2007

GOLDMAN SACHS ASSET MANAGEMENT, L.P.

By: /s/ Lauren LoFaro

-----  
Name: Lauren LoFaro  
Title: Attorney-in-fact

Page 4 of 4 pages